Ultra-sensitive NGS-based liquid biopsy technology in CDx

QIAGEN and Sysmex Inostics have recently announced a global alliance for the development and commercialization of cancer companion diagnostics (CDx). The partnership capitalizes on Sysmex Inostics’ Plasma-Safe-SeqS (SafeSEQ), an ultra-sensitive next generation sequencing (NGS) liquid biopsy technology and leverages QIAGEN’s experience in developing and commercializing companion diagnostics.

Learn more about:
  • Embracing opportunity through the QIAGEN-Sysmex partnership
  • The Power of SafeSEQ: Technology and performance overview
  • Realizing the clinical value of ultra-sensitive technology
Play the webinar preview
Speak with an expert
Discover how QIAGEN’s NGS CDx capabilities can advance your CDx development and global commercialization.
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.